IPO Timeline
Broker Results (T-2)
2022-12-28
Some brokers release in afternoon
Grey Market (T-1)
2022-12-29
Afternoon
HKEX Allotment (T-1)
2022-12-29
Evening
Registrar Allotment (T-1)
2022-12-29
Evening
Listing Day (T)
2022-12-30
First day of trading
Company Overview
| Stock Name | 康沣生物－Ｂ |
|---|---|
| Stock Code | 06922 |
| Company Full Name | 康沣生物－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家成立于2013年的中國醫療器械公司，主要專注于微創介入冷凍治療領域，擁有兩款核心產品，即膀胱冷凍消融系統及內鏡吻合夾。 |
| Listing Date | 2022-12-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區康新公路3399弄15號樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.cryofocus.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 18.90 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 20,997,900 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 0 lots | 5 | HK$ 0 |
| 0 lots | 10 | HK$ 0 |
| 0 lots | 20 | HK$ 0 |
| 0 lots | 25 | HK$ 0 |
| 1 lots | 200 | HK$ 0 |
| 2 lots | 400 | HK$ 0 |
| 3 lots | 600 | HK$ 0 |
| 4 lots | 800 | HK$ 0 |
| 5 lots | 1,000 | HK$ 0 |
| 6 lots | 1,200 | HK$ 0 |
| 7 lots | 1,400 | HK$ 0 |
| 8 lots | 1,600 | HK$ 0 |
| 9 lots | 1,800 | HK$ 0 |
| 10 lots | 2,000 | HK$ 0 |
| 15 lots | 3,000 | HK$ 0 |
| 20 lots | 4,000 | HK$ 0 |
| 25 lots | 5,000 | HK$ 0 |
| 30 lots | 6,000 | HK$ 0 |
| 35 lots | 7,000 | HK$ 0 |
| 40 lots | 8,000 | HK$ 0 |
| 50 lots | 10,000 | HK$ 0 |
| 75 lots | 15,000 | HK$ 0 |
| 100 lots | 20,000 | HK$ 0 |
| 125 lots | 25,000 | HK$ 0 |
| 150 lots | 30,000 | HK$ 0 |
| 250 lots | 50,000 | HK$ 0 |
| 300 lots | 60,000 | HK$ 0 |
| 400 lots | 80,000 | HK$ 0 |
| 500 lots | 100,000 | HK$ 0 |
| 1,000 lots | 200,000 | HK$ 0 |
| 1,250 lots | 250,000 | HK$ 0 |
| 29,590 lots | 5,918,000 | HK$ 0 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 17.66 |
|---|---|
| First Day Open | HK$ 18.5 |
| First Day Change | -6.56% |
| First Day Volume | 771400.0 |
| First Day Turnover | 14154600.0 |
Use of Proceeds
| Use of Proceeds | 1、58.2%或約81.4百萬港元將用于為膀胱冷凍消融系統的研發活動、商業推廣（包括銷售及營銷）及制造提供資金； 2、15.7%或約22.0百萬港元將用于為內鏡吻合夾的研發活動、商業推廣（包括銷售及營銷）及制造提供資金； 3、6.1%或約8.5百萬港元將分配予心臟冷凍消融系統的研發活動、計劃商業推廣及制造； 4、20.0%或約28.0百萬港元將分配予目前產品管線的其余14款在研產品的研發活動、注冊備案、計劃商業推廣及制造。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
花旗环球金融亚洲有限公司 CE AAA137
华泰金融控股（香港）有限公司 CE AOK809
Overall Coordinators (4)
花旗环球金融亚洲有限公司 CE AAA137
华泰金融控股（香港）有限公司 CE AOK809
招银国际融资有限公司 CE AVM940
农银国际证券有限公司 CE ACX411
Joint Bookrunners (7)
花旗环球金融亚洲有限公司 CE AAA137
华泰金融控股（香港）有限公司 CE AOK809
招银国际融资有限公司 CE AVM940
农银国际证券有限公司 CE ACX411
交银国际证券有限公司 CE APJ121
富途证券国际（香港）有限公司 CE AZT137
老虎证券（香港）环球有限公司 CE BMU940
Joint Lead Managers (8)
花旗环球金融亚洲有限公司 CE AAA137
华泰金融控股（香港）有限公司 CE AOK809
招银国际融资有限公司 CE AVM940
农银国际证券有限公司 CE ACX411
交银国际证券有限公司 CE APJ121
富途证券国际（香港）有限公司 CE AZT137
老虎证券（香港）环球有限公司 CE BMU940
元库证券有限公司 CE BLN458
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 李克儉 |
|---|---|
| Company Secretary | 劉偉,梁慧欣 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 寧波麟灃生物科技有限公司(26.61%),呂世文(9.15%),珠海高瓴鈞恒股權投資合伙企業(8.09%),上海仕地實業發展有限公司(5.98%),寧波脈尚投資合伙企業(5.36%),寧波弘盈康企業管理合伙企業(5.19%),蘇州新建元二期創投(5.14%) |
|---|
Subscription Tiers
IPO Timeline
